Tevogen grants director 75,000 restricted shares

A Tevogen Inc. director received a 75,000-share restricted stock grant that vests over three years, increasing her direct holdings.

Rhea-AI Filing Summary

Tevogen Inc. (symbol: TVGN) is the issuer of record for a Form 4 filing submitted to the SEC. PODLOGAR SUSAN M reported acquisition or exercise transactions in this Form 4 filing.

Tevogen Inc. (TVGN) reported that director Susan M. Podlogar received a grant of 75,000 shares of Common Stock as restricted stock on September 11, 2026 under the Tevogen Inc. 2024 Omnibus Incentive Plan. These shares will vest ratably in three equal annual installments starting September 11, 2027, contingent on continued service, leaving her with 123,678 shares of common stock held directly after the grant. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Grant/Award: 75,000 shares

Grant/Award 1 txn

Insider PODLOGAR SUSAN M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	75,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 123,678 shares (Direct)

Footnotes (1)

1. F1. Represents a grant of restricted stock under the Tevogen Inc. 2024 Omnibus Incentive Plan, which will vest ratably in three equal annual installments commencing on September 11, 2027, provided that the reporting person remains in service with the Issuer at such dates.

Key Figures

Restricted stock granted: 75,000 shares Price per share for grant: $0.00 per share Shares held after transaction: 123,678 shares +2 more

5 metrics

Restricted stock granted 75,000 shares Grant to director Susan M. Podlogar on September 11, 2026

Price per share for grant $0.00 per share Equity grant made at no cash cost to the director

Shares held after transaction 123,678 shares Director Susan M. Podlogar’s direct holdings after the grant

Vesting installments 3 equal annual installments Vesting under the 2024 Omnibus Incentive Plan starting September 11, 2027

Vesting commencement date September 11, 2027 Start of vesting for the 75,000 restricted shares

Key Terms

restricted stock, 2024 Omnibus Incentive Plan, vest ratably

3 terms

restricted stock financial

"Represents a grant of restricted stock under the Tevogen Inc. 2024 Omnibus Incentive Plan"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

2024 Omnibus Incentive Plan financial

"grant of restricted stock under the Tevogen Inc. 2024 Omnibus Incentive Plan"

vest ratably financial

"which will vest ratably in three equal annual installments commencing on September 11, 2027"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TVGN disclose for Susan M. Podlogar?

Tevogen Inc. disclosed that director Susan M. Podlogar received a grant of 75,000 restricted shares of Common Stock on September 11, 2026, under the 2024 Omnibus Incentive Plan, vesting over three years subject to continued service.

How many TVGN shares were granted in this Form 4 filing?

The filing reports a grant of 75,000 shares of Tevogen Inc. Common Stock as restricted stock to director Susan M. Podlogar on September 11, 2026.

What is the vesting schedule for the 75,000 TVGN restricted shares?

The 75,000 restricted shares will vest ratably in three equal annual installments beginning on September 11, 2027, as long as Susan M. Podlogar remains in service with Tevogen Inc. on those dates.

What are Susan M. Podlogar’s TVGN holdings after this grant?

After the reported grant, Susan M. Podlogar holds 123,678 shares of Tevogen Inc. Common Stock directly.

Was this TVGN insider grant made under a Rule 10b5-1 plan?

No. The filing indicates that the Rule 10b5-1 checkbox is not marked, so no Rule 10b5-1 trading plan is reported for this grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 08:05 PM Accepted by SEC EDGAR 09/15/2026 - 08:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PODLOGAR SUSAN M

(Last) (First) (Middle)

C/O TEVOGEN BIO HOLDINGS INC.

15 INDEPENDENCE BLVD, STE 410

(Street)

WARREN NEW JERSEY 07059

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tevogen Inc. [ TVGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2026		A		75,000(1)	A	$0.00	123,678	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock under the Tevogen Inc. 2024 Omnibus Incentive Plan, which will vest ratably in three equal annual installments commencing on September 11, 2027, provided that the reporting person remains in service with the Issuer at such dates.

	/s/ Kirti Desai, Attorney-in-Fact	09/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)